Companies/Insulet Corp.

Company profile

Insulet Corp.

NASDAQ: PODD · Healthcare · Medical - Devices

PublicHQ Acton, MACIK 0001145197Reports USD

#96 of 1,394 Healthcare companies by revenue72nd-percentile growth

EA Score

83B+

FH 85DQ 83GM 74SS 87

v0.1 · 65/100 weight · provisional

↑ Piotroski F, market scale · ↓ balance-sheet leverage, revenue growth (YoY)

Methodology →

Revenue TTM

$2.9B

Rev growth YoY (TTM)

+31.9%

Net income (FY)

$247.1M

Employees

5,400

Market cap

$11.4B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.7B$2.7B2025

Net income$247.1M$247.1M2025

Operating income$473.8M$473.8M2025

Total assets$3.2B$3.2B2025

Liabilities$1.7B$1.7B2025

Equity$1.5B$1.5B2025

Revenue trend

FY2019 – FY2025 · USD

$192.1M

FY19

$738.2M

FY19

$904.4M

FY20

$1.1B

FY21

$1.1B

FY22

$1.7B

FY23

$2.1B

FY24

$2.7B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

International Omnipod99%

Drug Delivery1%

By geography

UNITED STATES72%

Non-US28%

The read

Insulet Corp. booked $2.7B in FY2025 revenue, growing 31% year over year — faster than most Healthcare companies we track, at a 9.1% net margin.

Peers · Healthcare

BioMarin Pharmaceutical Inc.85A Charles River Laboratories International, Inc.73B Bio-Techne Corporation85A Baxter International Inc.78B+

Key facts

CEOAshley McEvoy

SectorHealthcare

IndustryMedical - Devices

HeadquartersActon, MA

ExchangeNASDAQ: PODD

Employees5,400

IPO date2007-05-15

Latest filings

8-K2026-06-25 8-K2026-05-26 8-K2026-05-21 10-Q2026-05-06 8-K2026-05-06 8-K2026-04-29 DEF 14A2026-04-06 8-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.